Learning about alpha-synuclein protein in brain health and disease
Part of Brain & nervous system, Mental health clinical trials.
This study helps people understand a protein called alpha-synuclein that may be related to memory problems and movement disorders. Researchers will either test your spinal fluid or skin to look for this protein, then discuss the results with you and measure how you're doing over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can give permission for the study yourself, or have a caregiver give permission for you
- You see a primary care doctor or neurologist regularly for your health
- You're willing to have a skin biopsy or spinal tap (lumbar puncture) to test for alpha-synuclein, or you already have test results we can use
- If you're healthy: Your thinking and memory are normal (score 26–30 on a mental test), and you have no serious illnesses
- If you have symptoms: A neurologist or movement disorder specialist has referred you and you have been diagnosed with or may have Lewy body disease, Parkinson's disease, or related conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how brain function changes over time in people with Lewy body disease or Alzheimer's. Researchers will use memory tests, MRI scans, and EEG (a painless brain-wave recording) to track these changes, and you will need a family member or friend to help report on your daily life.
This study tracks changes in people with Parkinson's disease, other movement disorders, or cognitive decline to find better ways to measure disease progression.
This study tests donanemab, an investigational drug designed to target amyloid proteins in the brain that may contribute to cognitive decline in people with early dementia with Lewy bodies. The trial aims to see if this treatment can slow cognitive decline and help preserve thinking and memory.
This trial follows people with probable Lewy body dementia over several years to see how the brain changes on MRI and on memory/thinking tests. It may help researchers understand disease progression and improve future care for Lewy body dementia.
This trial looks at brain wave patterns (EEG) and nerve damage in people with Lewy body disease. It uses past data from a study called Alpha-Lewy-MA and a special test (RT-QuIC) to learn more about the disease.
This early-stage study tests whether ambroxol can act as a “disease-modifying” treatment for Lewy body dementia, meaning it aims to change how the illness progresses rather than only relieve symptoms. You may be asked to complete brain testing and have stable medications while the study monitors memory, thinking, and safety.
Hear when a new Lewy Body Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.